{"id":"NCT01734993","sponsor":"Hoffmann-La Roche","briefTitle":"A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).","officialTitle":"A Multicenter, Open-Label Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2015-09","completion":"2015-09","firstPosted":"2012-11-28","resultsPosted":"2016-11-28","lastUpdate":"2016-11-28"},"enrollment":11,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Tocilizumab","otherNames":["RoActemra","Actemra"]}],"arms":[{"label":"Tocilizumab","type":"EXPERIMENTAL"}],"summary":"This multicenter, open-label, single arm, interventional, long-term extension (LTE) study will evaluate the safety and efficacy of tocilizumab (TCZ, RoActemra/Actemra) in French participants with moderate to severe RA who have completed the Week 97 visit of WA22762 LTE study (NCT01194414) (EudraCT Number 2010-018375-22). Participants from France, who completed the Week 97 visit of the WA22762 LTE study and considered as responders (defined as having improvement in disease activity score based on 28-joint count \\[DAS28\\] of greater than \\[\\>\\] 1.2 points) will continue TCZ treatment within this local LTE study for a maximum of 156 weeks of subcutaneous (SC) TCZ treatment, or until SC TCZ becomes commercially available, whichever occurs first.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Baseline up to approximately 142 weeks","effectByArm":[{"arm":"Tocilizumab","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":6,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":11},"commonTop":["Bronchitis","Arthralgia","Urinary tract infection","Nasopharyngitis","Rhinitis"]}}